The Readout Loud
A podcast by STAT - Joi
350 Episoade
-
346: Zealand's obesity strategy and Immunovant's curious development plan
Publicat: 20.03.2025 -
345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
Publicat: 13.03.2025 -
344: Trump's FDA commissioner nominee takes the hot seat
Publicat: 06.03.2025 -
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
Publicat: 27.02.2025 -
342: FDA cuts, zombie biotechs, and too much weight loss?
Publicat: 20.02.2025 -
341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
Publicat: 13.02.2025 -
340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug
Publicat: 06.02.2025 -
339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
Publicat: 30.01.2025 -
338: Chinese biotechs, a WHO departure, and post-JPM thoughts
Publicat: 23.01.2025 -
337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
Publicat: 15.01.2025 -
336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study
Publicat: 09.01.2025 -
335: A deep dive on Makary, Vertex's pain data, & 2025 predictions
Publicat: 19.12.2024 -
334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children
Publicat: 12.12.2024 -
333: An H5N1 bird flu update and talent scarcity in the radiopharma field
Publicat: 05.12.2024 -
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?
Publicat: 21.11.2024 -
331: AbbVie’s stumble, Amgen’s tumble and more election fallout
Publicat: 14.11.2024 -
330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks
Publicat: 07.11.2024 -
329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story
Publicat: 31.10.2024 -
328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions
Publicat: 24.10.2024 -
327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
Publicat: 17.10.2024
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.